These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25181377)

  • 1. Psychosocial factors related to the use of InterStim® for the treatment of refractory overactive bladder.
    Levin PJ; Siddiqui NY; Wu JM; Amundsen CL
    Female Pelvic Med Reconstr Surg; 2014; 20(5):272-5. PubMed ID: 25181377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom severity and patient perceptions in overactive bladder: how are they related?
    Homma Y; Gotoh M
    BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
    Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
    Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
    Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
    Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
    Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
    BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does site of pelvic organ prolapse repair affect overactive bladder symptoms?
    Dieter AA; Edenfield AL; Weidner AC; Siddiqui NY
    Female Pelvic Med Reconstr Surg; 2014; 20(4):203-7. PubMed ID: 24978085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
    Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
    Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.
    Zinner N; Kobashi K; Koochaki P; Fix D; Egermark M
    Neurourol Urodyn; 2011 Jan; 30(1):62-8. PubMed ID: 20860020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should we use the shorter Thai-version quality of life and symptoms questionnaires in women with overactive bladder?
    Bunyavejchevin S; Liao L; Lu SH; Choo MS; Rabbani KJ; Havanond P
    J Obstet Gynaecol Res; 2015 Aug; 41(8):1260-5. PubMed ID: 26081949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linguistic validation of the N-QOL (ICIQ), OAB-q (ICIQ), PPBC, OAB-S and ICIQ-MLUTSsex questionnaires in 16 languages.
    McKown S; Abraham L; Coyne K; Gawlicki M; Piault E; Vats V
    Int J Clin Pract; 2010 Nov; 64(12):1643-52. PubMed ID: 20722767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.
    Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C
    BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
    Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
    Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.